Skip to Main Content

Filter:

Reviews

1 Results

Review article
Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents
Journal of Adolescent Health
Vol. 63Issue 3p269–279Published in issue: September, 2018
- Lidia C. Serra
- Laura J. York
- Paul Balmer
- Chris Webber
Cited in Scopus: 8
MenACWY-TT (Nimenrix) is a quadrivalent meningococcal vaccine containing polysaccharides from serogroups A, C, W, and Y conjugated to a tetanus toxoid carrier protein. MenACWY-TT is licensed in some countries as a three-dose primary series in individuals as young as 6 weeks of age and as a single dose in individuals ≥12 months of age. MenACWY-TT use is supported by long-term immunogenicity and safety across age groups, including data from several phase 2, 3, and 4 clinical studies in adolescents and young adults.